1. Volume 14, Issue 5, Pages 497-505 (May 2015)
Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator 
Dr Jacqueline Palace, DM, Martin Duddy, MD, Thomas Bregenzer, PhD, Michael Lawton, MPhil, Feng Zhu, MSc, Mike Boggild, MD, Benjamin Piske, MSc, Prof Neil P Robertson, MD, Joel Oger, DM, Helen Tremlett, PhD, Prof Kate Tilling, PhD, Prof Yoav Ben-Shlomo, PhD, Charles Dobson, PhD 
The Lancet Neurology 
Volume 14, Issue 5, Pages (May 2015)
DOI: /S (15)
Copyright © 2015 Elsevier Ltd Terms and Conditions

2. Figure Study profile for the UK Risk Sharing Scheme
Data was taken from the year 8 locked dataset; follow-up data after year 6 were used only in secondary analyses to impute missing year 6 values. RSS=Risk Sharing Scheme. RRMS=relapsing-remitting multiple sclerosis. SPMS=secondary progressive multiple sclerosis. EDSS=Expanded Disability Status Scale. DMT=disease-modifying therapy. ABN=Association of British Neurologists. *Other eligibility criteria not met or “not eligible” ticked on withdrawal form.
The Lancet Neurology  , DOI: ( /S (15) )
Copyright © 2015 Elsevier Ltd Terms and Conditions